LabCorp has received a new emergency authorization from the FDA for a COVID-19 test that does not require the use of chemical reagents to free the coronavirus’s RNA from a sample.

President Donald Trump’s COVID-19 diagnosis is raising fresh questions about the White House’s strategy for testing and containing the virus for a president whose cavalier attitude about the coronavirus has persisted since it landed on American shores.

Tumor cells are better at forming potentially deadly metastases when they move as part of clumps rather than on their own. But the molecular mechanisms driving the aggressive growth of these multicellular tumor clusters are unclear.

French biotech Genfit is on its way out of fatty liver R&D after a phase 3 flop, but compatriot Poxel is on its way up. The latter’s nonalcoholic steatohepatitis (NASH) treatment beat placebo at reducing liver fat in a phase 2 study, offering hope that Poxel’s approach could succeed where others have failed.

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics has added another $110 million to its coffers as it looks to expand further into the U.S. and Asia.

Genentech has secured a global license to neoantigen cancer vaccines developed by Vaccibody. The Roche subsidiary is set to hand over $200 million in upfront and near-term payments to access the fruits of Vaccibody’s efforts to overcome the limitations of cancer vaccines.

Netherlands-based biotech Vico Therapeutics has signed up biopharma veteran Rupert Sandbrink, M.D., Ph.D., as its new chief medical officer.

French biotech Genfit is cutting its way out of its phase 3 nonalcoholic steatohepatitis (NASH) disaster in the summer and cresting two new units.

Human behavior relies on the excitation and inhibition of neurons, and scientists have long believed that neurons themselves are largely responsible for keeping this circuit of activity in balance. But now, a research team led by the Icahn School of Medicine at Mount Sinai has found that immune cells in the brain also play a crucial role in the regulation of behavior.

Medtronic has moved to acquire Avenu Medical, developers of a minimally invasive method of building the blood vessel access ports used by patients receiving dialysis treatments.